Natural carriers for application in tuberculosis treatment

Journal of Microencapsulation

Volumn 30, Issue 3, 2013, Pages 295-306

  Costa, Hugo ^a   Grenha, Ana ^a  

^a UNIVERSITY OF ALGARVE   (Portugal)

Author keywords

Controlled release; Drug delivery; Microencapsulation; Microparticles; Nanoparticles

Indexed keywords

ALBUMIN; ALGINIC ACID; CARBOXYMETHYLCELLULOSE; CHITOSAN; DRUG CARRIER; ECONAZOLE; ETHAMBUTOL; GELATIN; GLUCOSAMINE; GLUCURONIC ACID; HYALURONIC ACID; ISONIAZID; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; LIPID; MANNITOL; MANNOSE; MANNURONIC ACID; MICROSPHERE; N ACETYLGLUCOSAMINE; NANOPARTICLE; OFLOXACIN; POLYMER; POLYSACCHARIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; SOLID LIPID NANOPARTICLE; STEARIC ACID; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CHEMICAL COMPOSITION; COLONY FORMING UNIT; CONTROLLED RELEASE FORMULATION; COST; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; GELATION; HUMAN; HYDROPHILICITY; MEAN RESIDENCE TIME; MICROENCAPSULATION; NONHUMAN; PARTICLE SIZE; SUSTAINED DRUG RELEASE; TABLET FORMULATION;

ANTITUBERCULAR AGENTS; DRUG CARRIERS; HUMANS; PATIENT COMPLIANCE; TUBERCULOSIS;

EID: 84875835304     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2012.726283     Document Type: Article

References (70)

1. Ahmad Z, Maqbool M, Raja A. Nanomedicine for tuberculosis: Insights from animal models. Int J Nano Dimens, 2011;2: 67-84.
2. Ahmad Z, Pandey R, Sharma S, Khuller GK. Alginate nanoparticles as antituberculosis drug carriers: Formulation development, pharmacokinetics and therapeutic potential. Indian J Chest Dis Allied Sci, 2006a;48: 171-6.
3. Ahmad Z, Pandey R, Sharma S, Khuller GK. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. FEMS Microbiol Lett, 2006b;261: 181-6. (Pubitemid 44134150)
4. Ahmad Z, Pandey R, Sharma S, Khuller GK. Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses. Int J Antimicrob Agents, 2006c;27: 409-16.
5. Ahmad Z, Sharma S, Khuller GK. In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv. FEMS Microbiol Lett, 2005a;251: 19-22. (Pubitemid 41306223)
6. Ahmad Z, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents, 2005b;26: 298-303. (Pubitemid 41338657)
7. Ahmad Z, Sharma S, Khuller GK. The potential of azole antifungals against latent/persistent tuberculosis. FEMS Microbiol Lett, 2006d;258: 200-3.
8. Ahmad Z, Sharma S, Khuller GK. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis. Nanomed Nanotechnol Biol Med, 2007;3: 239-43. (Pubitemid 47332342)
9. Ahsan F, Rivas IP, Khan MA, Torres Suárez AI. Targeting to macrophages: Role of physicochemical properties of particulate carriers - liposomes and microspheres - on the phagocytosis by macrophages. J Control Release, 2002;79: 29-40. (Pubitemid 34164159)
10. Ain Q, Sharma S, Khuller GK, Garg S. Alginate-based oral drug delivery system for tuberculosis: Pharmacokinetics and therapeutic effects. J Antimicrob Chemother, 2003;51: 931-8. (Pubitemid 36503426)
11. Al-Qadi S, Grenha A, Carrión-Recio D, Seijo B, Remuñán-López C. Microencapsulated chitosan nanoparticles for pulmonary protein delivery: In vivo evaluation of insulin-loaded formulations. J Control Release, 2012;157: 383-90.
12. Al-Qadi S, Grenha A, Remuñán-López C. Microspheres loaded with polysaccharide nanoparticles for pulmonary delivery: Preparation, structure and surface analysis. Carbohydr Polym, 2011;86: 25-34.
13. Anwunobi A, Emeje M. Recent applications of natural polymers in nanodrug delivery. J Nanomed Nanotechnol, 2011;S4: 2-7.
14. Armstead A, Li B. Nanomedicine as an emerging approach against intracellular pathogens. Int J Nanomed, 2011;6: 3281-93.
15. Attama A. SLN, NLC, LDC: State of the art in drug and active delivery. Recent Patents Drug Deliv Formulation, 2011;5: 178-87.
16. Azarmi S, Roa WH, Löbenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev, 2008;60: 863-75.
17. Barrow W. Microsphere technology for chemotherapy of mycobacterial infections. Curr Pharm Des, 2004;10: 3275-84. (Pubitemid 39276615)
18. Beneke C, Viljoen A, Hamman J. Polymeric plant-derived excipients in drug delivery. Molecules, 2009;14: 2602-20.
19. Blasi P, Schoubben A, Giovagnoli S, Rossi C, Ricci M. Fighting tuberculosis: Old drugs, new formulations. Expert Opin Drug Deliv, 2009;6: 977-93.
20. Borges O, Cordeiro-da-Silva A, Romeijn SG, Amidi M, de Sousa A, Borchard G, Junginger HE. Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. J Control Release, 2006;114: 348-58. (Pubitemid 44310817)
21. Braz L, Dionísio M, Grenha A. 2011. Chitosan-based nanocarriers: Effective vehicles for mucosal protein delivery. In: Davis S, ed. Chitosan manufacture, properties and usage. New York: Nova Science Publishers, pp. 365-412.
22. Cai Z, Wang Y, Zhu L-J, Liu Z-Q. Nanocarriers: A general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs. Curr Drug Metab, 2010;11: 197-207.
23. Cavalli R, Bargoni A, Podio V, Muntoni E, Zara GP, Gasco MR. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci, 2003;92: 1085-94. (Pubitemid 36523455)
24. Chiellini F, Piras AM, Errico C, Chiellini E. Micro/nanostructured polymeric systems for biomedical and pharmaceutical applications. Nanomedicine, 2008;3: 367-93. (Pubitemid 351827313)
25. Devi N, Maji T. Preparation and evaluation of gelatin/sodium carboxymethyl cellulose polyelectrolyte complex microparticles for controlled delivery of isoniazid. AAPS PharmSciTech, 2009;10: 1412-9.
26. Doherty T, Andersen P. Vaccines for tuberculosis: Novel concepts and recent progress. Clin Microbiol Rev, 2005;18: 687-702. (Pubitemid 41504511)
27. du Toit L, Pillay V, Danckwerts M. Tuberculosis chemotherapy: Current drug delivery approaches. Respir Res, 2006;7: 118-35.
28. Dyala'A GG, Malinconico M, Laurienzo P. Marine derived polysaccharides for biomedical applications: Chemical modification approaches. Molecules, 2008;13: 2069-106.
29. Florence A. The oral absorption of micro- and nanoparticulates: Neither exceptional nor unusual. Pharm Res, 1997;14: 259-66. (Pubitemid 27160935)
30. Fonte P, Andrade F, Araújo F, Andrade C, Neves J, Sarmento B. Chitosancoated solid lipid nanoparticles for insulin delivery. Methods Enzymol, 2012;508: 295-314.
31. Geiser M. Update on macrophage clearance of inhaled micro- and nanoparticles. J Aerosol Med Pulm Drug Deliv, 2010;23: 207-17.
32. George M, Abraham TE. Polyionic hydrocolloids for the intestinal delivery of protein drugs: Alginate and chitosan - a review. J Control Release, 2006;114: 1-14. (Pubitemid 44131680)
33. Grabovac V, Guggi D, Bernkop-Schnurch A. Comparison of the mucoadhesive properties of various polymers. Adv Drug Deliv Rev, 2005;57: 1713-23. (Pubitemid 41443475)
34. Grenha A, Remuñán-López C, Carvalho ELS, Seijo B. Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. Eur J Pharm Biopharm, 2008;69: 83-93.
35. Grenha A, Seijo B, Remuñán-López C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci, 2005;25: 427-37. (Pubitemid 40853870)
36. Hans M, Lowman A. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci, 2002;6: 319-27. (Pubitemid 36238389)
37. Hirota K, Tomoda K, Inagawa H, Kohchi C, Soma G-I, Makino K, Terada H. Stimulation of phagocytic activity of alveolar macrophages toward artificial microspheres by infection with mycobacteria. Pharm Res, 2008;25: 1420-30.
38. Hunter RL. On the pathogenesis of post primary tuberculosis: The role of bronchial obstruction in the pathogenesis of cavities. Tuberculosis, 2011;91(Suppl. 1):S6-10.
39. Hwang SM, Kim DD, Chung SJ, Shim CK. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis. J Control Release, 2008;129: 100-6.
40. Lehr C-M, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm, 1992;78: 43-8.
41. Lewis C, Mcgee JD. 1992. The macrophage. Oxford: IRL Press.
42. Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev, 2008;60: 1650-62.
43. Lu E, Franzblau S, Onyuksel H, Popescu C. Preparation of aminoglycosideloaded chitosan nanoparticles using dextran sulphate as a counterion. J Microencapsul, 2009;26: 346-54.
44. Malafaya P, Silva G, Reis R. Natural-origin polymers as carriers and scaffolds for biomolecules and cell delivery in tissue engineering application. Adv Drug Deliv Rev, 2007;59: 207-33. (Pubitemid 46879967)
45. Martins S, Sarmento B, Ferreira D, Souto E. Lipid-based colloidal carriers for peptide and protein delivery - Liposomes versus lipid nanoparticles. Int J Nanomed, 2007;2: 595-607.
46. Misra A, Hickey AJ, Rossi C, Borchard G, Terada H, Makino K, Fourie PB, Colombo P. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis, 2011;91: 71-81.
47. Mitchison DA, Fourie PB. The near future: Improving the activity of rifamycins and pyrazinamide. Tuberculosis, 2010;90: 177-81.
48. Mizoe T, Ozeki T, Okada H. Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microspheres. AAPS PharmSciTech, 2008;9: 755-61.
49. Mizrahy S, Peer D. Polysaccharides as building blocks for nanotherapeutics. Chem Soc Rev, 2012;41: 2623-40.
50. Mosser D. The many faces of macrophage activation. J Leukoc Biol, 2003;73: 209-12. (Pubitemid 36158295)
51. Murata Y, Jinno D, Liu D, Isobe T, Kofuji K, Kawashima S. The drug release profile from calcium-induced alginate gel beads coated with an alginate hydrolysate. Molecules, 2007;12: 2559-66.
52. Nimje N, Agarwal A, Saraogi GK, Lariya N, Rai G, Agrawal H, Agrawal GP. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. J Drug Target, 2009;17: 777-87.
53. Pandey R, Ahmad Z. Nanomedicine and experimental tuberculosis: Facts, flaws, and future. Nanomed Nanotechnol Biol Med, 2011;7: 259-72.
54. Pandey R, Khuller GK. Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers. J Antimicrob Chemother, 2004;53: 635-40. (Pubitemid 38499780)
55. Pandey R, Khuller GK. Antitubercular inhaled therapy: Opportunities, progress and challenges. J Antimicrob Chemother, 2005a;55: 430-5. (Pubitemid 40542580)
56. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis, 2005b;85: 227-34. (Pubitemid 40805619)
57. Pandey R, Sharma S, Khuller GK. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis, 2005;85: 415-20. (Pubitemid 41617396)
58. Pinheiro M, Lúcio M, Lima J, Reis S. Liposomes as drug delivery systems for the treatment of TB. Nanomedicine, 2011;6: 1413-28.
59. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomed Nanotechnol Biol Med, 2006;2: 8-21.
60. Ranjita S, Loaye A, Khalil M. Present status of nanoparticle research for treatment of tuberculosis. J Pharm Pharm Sci, 2011;14: 100-16.
61. Russell D. Who puts the tubercle in tuberculosis? Nat Rev Microbiol, 2007;5: 39-47. (Pubitemid 44942302)
62. Saraogi GK, Gupta P, Gupta UD, Jain NK, Agrawal GP. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int J Pharm, 2010;385: 143-9.
63. Saraogi GK, Sharma B, Joshi B, Gupta P, Gupta UD, Jain NK, Agrawal GP. Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis. J Drug Target, 2011;19: 219-27.
64. Smola M, Vandamme T, Sokolowski A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int J Nanomed, 2008;3: 1-19. (Pubitemid 351517072)
65. Sosnik A, Carcaboso Á M, Glisoni RJ, Moretton MA, Chiappetta DA. New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev, 2010;62: 547-59.
66. Sudhakar Y, Kuotsu K, Bandyopadhyay A. Buccal bioadhesive drug delivery - A promising option for orally less efficient drugs. J Control Release, 2006;114: 15-40. (Pubitemid 44128620)
67. Taylor P, Martinez-Pomares L, Stacey M, Lin H-H, Brown G, Gordon S. Macrophage receptors and immune recognition. Annu Rev Immunol, 2005;23: 901-44. (Pubitemid 40563189)
68. Yadav AB, Singh AK, Verma RK, Mohan M, Agrawal AK, Misra A. The devil's advocacy: When and why inhaled therapies for tuberculosis may not work. Tuberculosis, 2011;91: 65-6.
69. Yeboah KG, Douza'S MJ. Evaluation of albumin microspheres as oral delivery system for Mycobacterium tuberculosis vaccines. J Microencapsul, 2009;26: 166-79.
70. Zara GP, Bargoni A, Cavalli R, Fundaro A, Vighetto D, Gasco MR. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm Sci, 2002;91: 1324-33. (Pubitemid 34651194)